NCT00694330

Brief Summary

This research study is testing the safety of a vaccination of cells called GM-K562 cells mixed with the participants own irradiated tumor cells. The GM-K562 cells have been modified in the laboratory to secrete the protein GM-CSF. This protein can be effective in stimulating an immune response to cancer. This newly developed vaccine may stop cancer cells from growing.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jun 2008

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2008

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

June 6, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 10, 2008

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2009

Completed
Last Updated

June 22, 2017

Status Verified

March 1, 2017

Enrollment Period

1.2 years

First QC Date

June 6, 2008

Last Update Submit

June 20, 2017

Conditions

Glioma

Keywords

vaccineGM-K562malignant glioma

Outcome Measures

Primary Outcomes (2)

  • To determine the feasibility of preparing lethally irradiated autologous glioma cells for use in combination with irradiated GM-K562 cells as vaccination therapy in this patient population.

    3 years

  • To determine the safety and biological activity of subcutaneous and intradermal injection of irradiated autologous malignant glioma cells mixed with irradiated GM-CSF producing GM-K562 cells in this patient population.

    3 years

Secondary Outcomes (2)

  • Progression free survival

    3 years

  • overall survival

    5 years

Study Arms (1)

GM-K562 Vaccination

EXPERIMENTAL
Biological: GM-K562 Vaccination

Interventions

GM-K562 VaccinationBIOLOGICAL

Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.

GM-K562 Vaccination

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must have recurrent malignant glioma, having already been diagnosed with and treated for biopsy-proven glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma or gliosarcoma.
  • Patients will already have been treated with external beam irradiation with or without chemotherapy.
  • Patients must be able to undergo a MRI.
  • A priori clinical indication for open resection/debulking of recurrent malignant glioma.
  • At the time of vaccination, patients must be at least 4 weeks from completion of radiotherapy and 4 weeks from cytotoxic chemotherapy.
  • Serum absolute neutrophil count greater than or equal to 1500/mm3
  • Serum platelets greater than or equal to 50,000/mm3
  • Serum sodium greater than or equal to 125 mmol/L
  • years of age or older
  • Karnofsky Performance Score of 60% or greater

You may not qualify if:

  • Uncontrolled active infection
  • Pregnancy or nursing mothers
  • HIV infection
  • Evidence of active infection with Hepatitis B or C
  • Concurrent malignancy
  • Active or clinically relevant autoimmune disease
  • Urgent need for surgical decompression (at the time of initial consultation)
  • Previous participation in a gene therapy or immunotherapy trial
  • Inability to provide informed consent because of altered mental status or mental illness
  • Any other medical, surgical or psychiatric condition which could interfere with the patient's inability to comply with protocol regimen

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States

Location

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Study Officials

  • William Curry, MD

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 6, 2008

First Posted

June 10, 2008

Study Start

June 1, 2008

Primary Completion

August 1, 2009

Study Completion

August 1, 2009

Last Updated

June 22, 2017

Record last verified: 2017-03

Locations

US(2)